Bicara Therapeutics (BCAX) Status Update summary

Mechanism and clinical rationale

• Ficerafusp alfa, an EGFR/TGF-β bifunctional antibody, is designed to inhibit TGF-β at the tumor, breaking down fibrotic barriers and enabling immune cell penetration in HPV-negative head and neck cancer.

• Mechanistic data show downregulation of phospho-SMAD2 and EMT pathways, increased CD8+ T-cell infiltration, and immune cell activation, supporting the drug's tumor-penetrating and resistance-reversing effects.

• These effects are linked to deep and durable tumor responses, with clinical images and patient cases demonstrating rapid and complete tumor resolution and symptom relief.

Clinical efficacy and safety update

• In phase IB, ficerafusp alfa plus pembrolizumab achieved a 54% confirmed response rate and 89% disease control rate in HPV-negative patients, with 80% of responders showing at least 80% tumor shrinkage.

• Median progression-free survival was just under 10 months, and median duration of response reached 21.7 months, with 46% two-year overall survival, more than doubling historical benchmarks.

• Safety profile remains manageable, with most adverse events being mild and consistent with known EGFR or TGF-β inhibition effects.

Comparative context and patient population

• The study population had high disease burden, with 47% presenting bulky tumors and balanced CPS scores, mirroring real-world and prior trial demographics.

• Ficerafusp alfa nearly triples response rates compared to pembrolizumab alone, while maintaining immunotherapy-like durability, addressing a key unmet need in HPV-negative disease.

• Deep responses (≥80% shrinkage) are strongly correlated with improved duration of response, PFS, and overall survival, regardless of CPS score.